(Q46919795)

26 December 2017

title

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer (English)

1 reference

26 December 2017

1 reference

1 reference

Darshan A Mehta

1

1 reference

26 December 2017

Joel W Hay

series ordinal

2

1 reference

26 December 2017

language of work or name

English

0 references

publication date

23 January 2014

1 reference

26 December 2017

published in

Gynecologic Oncology

1 reference

26 December 2017

volume

132

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

677-683

1 reference

26 December 2017

Ovarian cancer, version 3.2012.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Ten-year relative survival for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Simplified calculation of body-surface area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Patient time costs associated with cancer care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Estimating the cost of informal caregiving for elderly patients with cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

Do oncologists believe new cancer drugs offer good value?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.021

10.1016/J.YGYNO.2014.01.021

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017